Latano-Q Comp.

Timolol maleate, the active ingredient in Latano-Q Comp., is a beta‑blocker presented as eye drops for ocular use. It reduces intra‑ocular pressure in patients with open‑angle glaucoma or ocular hypertension. Latanoprost, the second active ingredient, is a prostaglandin analog that enhances uveoscleral outflow, complementing timolol’s effect.

GNH USA supplies Latano‑Q Comp. as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Latano‑Q Comp. combines a beta‑blocker and a prostaglandin analog to lower intra‑ocular pressure in glaucoma and ocular hypertension.

Open‑angle glaucoma: reduces intra‑ocular pressure and slows disease progression. Ocular hypertension: lowers eye pressure to prevent conversion to glaucoma. Post‑surgical ocular pressure control: maintains target pressure after glaucoma surgery.

Common Side Effects: - Eye irritation or burning sensation - Blurred vision - Redness of the conjunctiva - Itching or mild allergic reaction - Dry eye or foreign‑body sensation - Increased eyelash growth

Serious or Rare Side Effects: - Severe allergic reaction (e.g., angio‑edema) - Ocular inflammation or uveitis - Paradoxical increase in intra‑ocular pressure - Systemic bradycardia or hypotension - Bronchospasm in susceptible individuals - Chest pain or worsening of cardiac conditions

Before initiating therapy, consider the following precautions: - Cardiovascular assessment: avoid in patients with severe bradycardia, heart block, or uncontrolled heart failure. - Respiratory history: use cautiously in asthma or COPD due to possible bronchoconstriction. - Ocular surface disease: defer use if active eye infection or severe dry eye is present. - Pregnancy and lactation: limited data; weigh potential benefits against risks. - Storage: Store at room temperature: keep bottle in original packaging, protect from light and moisture.

Latano‑Q Comp. may interact with other medications as follows:

Major Interactions (Avoid): - Systemic non‑selective beta‑blockers: additive bradycardia or hypotension. - Sympathomimetic agents (e.g., epinephrine eye drops): may diminish timolol efficacy. - Concurrent ocular prostaglandin analogs: increased risk of ocular inflammation.

Moderate Interactions (Monitor Closely):\n- Carbonic anhydrase inhibitors (systemic): may enhance intra‑ocular pressure reduction. - Topical corticosteroids: may reduce prostaglandin effect. - Antihistamine eye drops: possible additive ocular irritation.